The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Evaluation of olanzapine for breakthrough emesis in patients with cancer not responding to standard antiemetic regimen.
S. Chanthawong
No relevant relationships to disclose
S. Subongkot
No relevant relationships to disclose
A. Sookprasert
No relevant relationships to disclose